Another family member, c-myc (MYC), shares oncogenic ability to sustain multiple pathways leading to malignancy, but is reported to be expressed only in a small group of advanced NB showing poor clinical outcome identical to that of patients with amplification of the MYCN gene (28, 29). The gene discussed is MYC; the disease is neuroblastoma.